Mallinckrodt Pharmaceuticals Overview
- Year Founded
-
1866
- Status
-
Private
- Employees
-
3,371
- Latest Deal Type
-
Debt - Merger
- Financing Rounds
-
19
- Investments
-
18
Mallinckrodt Pharmaceuticals General Information
Description
Developer of specialty pharmaceutical products focused on improving outcomes for patients with severe and critical conditions. The company offers autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products, thereby enabling clients with precise drugs as per their health conditions.
Contact Information
Website
www.mallinckrodt.comCorporate Office
- College Business and Technology Park
- Cruiserath, Blanchardstown
- Dublin 15
- Ireland
Corporate Office
- College Business and Technology Park
- Cruiserath, Blanchardstown
- Dublin 15
- Ireland
Mallinckrodt Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mallinckrodt Pharmaceuticals Comparisons
Industry
Financing
Details
Mallinckrodt Pharmaceuticals Competitors (13)
One of Mallinckrodt Pharmaceuticals’s 13 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| MS Pharma | Private Equity-Backed | Amman, Jordan | ||||
| Genzyme Ireland | Corporation | Kilmeaden, Ireland | ||||
| Novo Nordisk | Corporation | Bagsvaerd, Denmark | ||||
| Verona Pharma | Corporate Backed or Acquired | London, United Kingdom |
Mallinckrodt Pharmaceuticals Patents
Mallinckrodt Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210290537-A1 | Liposomal elinafide formulations and uses thereof | Inactive | 08-Dec-2016 | ||
| WO-2018106980-A1 | Liposomal elinafide formulations and uses thereof | Inactive | 08-Dec-2016 | ||
| US-20200079785-A1 | Mitomycin c prodrug liposome formulations and uses thereof | Inactive | 08-Nov-2016 | ||
| WO-2018089481-A1 | Mitomycin c prodrug liposome formulations and uses thereof | Inactive | 08-Nov-2016 | ||
| US-20200001109-A1 | Methods for treating hyperbilirubinemia with stannsoporfin and phototherapy | Inactive | 12-May-2016 | A61N5/0621 |
Mallinckrodt Pharmaceuticals Signals
Mallinckrodt Pharmaceuticals Investments & Acquisitions (18)
Mallinckrodt Pharmaceuticals’s most recent deal was a Merger/Acquisition with Endo International for . The deal was made on 31-Jul-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Endo International | 31-Jul-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Endo (Pharmaceuticals) | 13-Mar-2025 | Merger/Acquisition | Pharmaceuticals | ||
| Sucampo Pharmaceuticals | 01-Feb-2018 | Merger/Acquisition | Pharmaceuticals | ||
| Ocera Therapeutics | 01-Dec-2017 | Merger/Acquisition | Biotechnology | ||
| InfaCare Pharmaceutical | 25-Sep-2017 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology |
Mallinckrodt Pharmaceuticals Exits (4)
Mallinckrodt Pharmaceuticals’s most recent exit was on 01-Feb-2016 from The Medicines Company. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| The Medicines Company | 01-Feb-2016 | Completed |
|
||
| Therakos | 25-Sep-2015 | Completed |
|
||
| Gablofen | 03-Oct-2012 | Completed |
|
||
| Tensys Medical | 27-Nov-2006 | Later Stage VC | Completed |
|
Mallinckrodt Pharmaceuticals Affiliates
Subsidiaries (15)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sucampo International Holdings | London, United Kingdom | 2020 | |
| Therakos Europe | Dublin, Ireland | 2018 | |
| Mallinckrodt Finance Management Ireland | Dublin, Ireland | 2015 | |
| Mallinckrodt Pharma Ip Trading Unlimited Company | Dublin, Ireland | 2015 | |
| Keenova International Holdings | Luxembourg, Luxembourg | 2015 |
Mallinckrodt Pharmaceuticals FAQs
-
When was Mallinckrodt Pharmaceuticals founded?
Mallinckrodt Pharmaceuticals was founded in 1866.
-
Where is Mallinckrodt Pharmaceuticals headquartered?
Mallinckrodt Pharmaceuticals is headquartered in Dublin, Ireland.
-
What is the size of Mallinckrodt Pharmaceuticals?
Mallinckrodt Pharmaceuticals has 3,371 total employees.
-
What industry is Mallinckrodt Pharmaceuticals in?
Mallinckrodt Pharmaceuticals’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Mallinckrodt Pharmaceuticals a private or public company?
Mallinckrodt Pharmaceuticals is a Private company.
-
What is Mallinckrodt Pharmaceuticals’s current revenue?
The current revenue for Mallinckrodt Pharmaceuticals is .
-
How much funding has Mallinckrodt Pharmaceuticals raised over time?
Mallinckrodt Pharmaceuticals has raised $2.82B.
-
Who are Mallinckrodt Pharmaceuticals’s competitors?
Pfizer (Vienna), MS Pharma, Genzyme Ireland, Novo Nordisk, and Verona Pharma are some of the 13 competitors of Mallinckrodt Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process